Harpoon Therapeutics and Roche to Collaborate on Clinical Trials to Study Novel Immuno-Oncology Combination for Small Cell Lung Cancer

Harpoon Therapeutics, Inc. announced that it has entered into a clinical supply agreement with F. Hoffmann-La Roche Ltd (Roche) to supply atezolizumab for use in the company’s HPN328, a DLL3 targeting TriTAC®, clinical development program.